Pharmacist Intervention in Risk Reduction Study: High-Risk Cardiac Patients

Objectives: Although there are guidelines for managing patients at high vascular risk, many people remain undertreated. This community-based study was designed to 1) measure the ability of the pharmacist—physician collaboration to affect a broad array of drug-related endpoints and 2) to compare 2 methods of training community pharmacists to collaborate with physicians on cardiac patient care. This paper focuses on the first outcome, and a companion paper will address the second outcome. Methods: We used a before-and-after design to assess pharmacists' ability to affect drug-related endpoints. We identified patients by various methods, one of which was medication profiles. Those providing consent were educated on risk factor modification and encouraged to consult their physicians. Pharmacists subsequently faxed the details of their assessments to the primary care physician, along with suggestions for therapy changes. Our outcome measure was the proportion of patients who achieved a composite of either a dose increase or a new target medication as a result of pharmacist recommendations during the study. Results: A total of 61 pharmacists recruited 217 patients, and of these, follow-up was completed on 216. Of the patients for whom a pharmacist made a suggestion, pharmacologic risk reduction therapy was initiated or enhanced in 53.7%. Conclusion: This community pharmacist—based program improved utilization of the therapies known to decrease vascular risk in patients considered high risk.

[1]  R. Slaughter,et al.  Pharmacists' Ability to Influence Outcomes of Hypertension Therapy , 1997, Pharmacotherapy.

[2]  B. Irons,et al.  A Retrospective Cohort Analysis of the Clinical Effectiveness of a Physician‐Pharmacist Collaborative Drug Therapy Management Diabetes Clinic , 2002, Pharmacotherapy.

[3]  M. Joffres,et al.  Awareness, treatment, and control of hypertension in Canada. , 1997, American journal of hypertension.

[4]  R. Clifford,et al.  Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. , 2005, Diabetes care.

[5]  R. Abbott,et al.  Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension , 1998, Journal of General Internal Medicine.

[6]  R. McPherson,et al.  Recommendations for the Management of Dyslipidemia and the Prevention of Cardiovascular Disease: 200 , 2003 .

[7]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[8]  S. Harris,et al.  Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). , 2005, Diabetes research and clinical practice.

[9]  D. Parra,et al.  Optimizing Drug Therapy in Patients with Cardiovascular Disease: The Impact of Pharmacist‐Managed Pharmacotherapy Clinics in a Primary Care Setting , 2002, Pharmacotherapy.

[10]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[11]  R. Abbott,et al.  The Physician and Pharmacist Team: An Effective Approach to Cholesterol Reduction , 1997, Journal of General Internal Medicine.

[12]  C. Rubino,et al.  Effect of a Clinical Pharmacist‐Managed Lipid Clinic on Achieving National Cholesterol Education Program Low‐Density Lipoprotein Goals , 2000, Pharmacotherapy.

[13]  R. McPherson,et al.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  K. Teo,et al.  A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). , 2002, Archives of internal medicine.

[15]  D. Gaudet,et al.  Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). , 2005, The Canadian journal of cardiology.

[16]  D. Malone,et al.  Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. , 2000, Pharmacotherapy.

[17]  Alexander G Logan,et al.  The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. , 2005, The Canadian journal of cardiology.

[18]  L. Jaber,et al.  Evaluation of a Pharmaceutical Care Model on Diabetes Management , 1996, The Annals of pharmacotherapy.

[19]  D. Malone,et al.  Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study , 2000 .